Talk:Glutamate receptor: Difference between revisions
Justindchien (talk | contribs) |
Justindchien (talk | contribs) |
||
Line 28: | Line 28: | ||
In addition, I suggest you consider discussing in greater detail the role of glutamate receptors in EAE and Multiple Sclerosis pathogenesis under the “Potential therapeutic applications” section. Drugs that interact with ionotropic glutamate receptors to suppress EAE have emerged over the last decade, and use of receptor antagonists to control EAE with the possibility of therapeutic application in MS has also been investigated. You can find this information at the url: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592583/. You list MS under “Neurogenerative diseases” (which should be changed to “Neurodegenerative diseases”)—perhaps consider combining the “Clinical Significance” and “Potential therapeutic applications” sections. [[User:Bergaa7|Bergaa7]] ([[User talk:Bergaa7|talk]]) 02:11, 24 November 2009 (UTC) |
In addition, I suggest you consider discussing in greater detail the role of glutamate receptors in EAE and Multiple Sclerosis pathogenesis under the “Potential therapeutic applications” section. Drugs that interact with ionotropic glutamate receptors to suppress EAE have emerged over the last decade, and use of receptor antagonists to control EAE with the possibility of therapeutic application in MS has also been investigated. You can find this information at the url: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592583/. You list MS under “Neurogenerative diseases” (which should be changed to “Neurodegenerative diseases”)—perhaps consider combining the “Clinical Significance” and “Potential therapeutic applications” sections. [[User:Bergaa7|Bergaa7]] ([[User talk:Bergaa7|talk]]) 02:11, 24 November 2009 (UTC) |
||
thank you for your suggestion, we are currently undergoing more research on your suggestion and may see a viable application to our article. |
|||
==Potential Additions== |
==Potential Additions== |
Revision as of 01:28, 26 November 2009
This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |
Template:Wikiproject MCB |
Glutamate receptor is currently a Biology and medicine good article nominee. Nominated by Justindchien (talk) at 01:25, 26 November 2009 (UTC) An editor has indicated a willingness to review the article in accordance with the good article criteria and will decide whether or not to list it as a good article. Comments are welcome from any editor who has not nominated or contributed significantly to this article. This review will be closed by the first reviewer. To add comments to this review, click discuss review and edit the page.
|
Suggestions for BI481 course
Hi,
You guys have made a great start on updating this article. I have a couple of suggestions:
- Citations. If you haven't seen this yet, please check out User:Diberri's Wikipedia template filling tool. Given a PubMed ID, one can quickly produce a formatted citation that can be copied and pasted into a Wikipedia article. This will save you an enormous amount of work and insures that the citations are displayed in a consistent manor.
- Introduction and conclusion sections are not normally included in Wikipedia articles. I have taken the liberty of merging the introduction into the lead section. The conclusion section should be integrated with the rest of the article.
- Organization. It appears that the sections of this article were written independently and then merged together. This is understable given the requirements of your course but the end result is that the article is not as cohesive as it should be. The section entitled "Types" contains a list of the mGluR subtypes while "Genetics" contains a list of the iGluR subtypes. These two sections should be merged. The "Pathology" and "Current research" sections contain the same type of information and probably should be merged together. The focus should be kept on the receptor and not research about the receptor.
Again, good work. Cheers. Boghog (talk) 10:54, 31 October 2009 (UTC)
Removed GA nomination
I want to note that I have removed the GA nomination for this article, because it was made without any discussion by an editor who has not responded to queries. If nobody is prepared to respond to issues, the GA process is a waste of a reviewer's time. If anybody is in fact prepared to make requested improvements, the article can be renominated at will. Looie496 (talk) 01:29, 12 November 2009 (UTC)
Sorry, a lot of things have come up and we are now more prepared to respond to any suggestions and comments.
Potential Revisions
First, you should revaluate the organization of subtopics beneath main headings, particularly in the “Clinical significance” section. It seems that the “Excitotoxicity” subtopic does not belong—make it its own heading, or, if appropriate, clarify its relevance to the clinical significance of glutamate receptors within the article. In addition, I suggest you consider discussing in greater detail the role of glutamate receptors in EAE and Multiple Sclerosis pathogenesis under the “Potential therapeutic applications” section. Drugs that interact with ionotropic glutamate receptors to suppress EAE have emerged over the last decade, and use of receptor antagonists to control EAE with the possibility of therapeutic application in MS has also been investigated. You can find this information at the url: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592583/. You list MS under “Neurogenerative diseases” (which should be changed to “Neurodegenerative diseases”)—perhaps consider combining the “Clinical Significance” and “Potential therapeutic applications” sections. Bergaa7 (talk) 02:11, 24 November 2009 (UTC)
thank you for your suggestion, we are currently undergoing more research on your suggestion and may see a viable application to our article.
Potential Additions
Hey guys I have a few things I suggest you include in your article. First, I think you should not only describe glutamate receptor function in neurons, but also describe their function in glial cells. Here are a couple articles I found on this subject: “Glial glutamate receptors: likely actors in brain signaling” by VIVIAN I. TEICHBERG and “News on glutamate receptors in glial cells” by Christian Steinhäuser and Vittorio Gallo. Second, I think you should add the loss of GSH production due to the malfunction of the xCT astrocyte transporter in your neurodegeneration section. Finally, it would be more informative to describe the NMDA receptor in more detail including serine/glycine coagonists, the antagonist binding sites (Zn site, Mg blocker, MK801/PCP binding site), and also NMDA’s role in silent synapses. Pat Bolan(talk) 2:28, 24 November 2009 (UTC)
Hi, we have linked to the other wikipedia article which talkes about NMDA receptors specifically. We are providing an overview for Glutamate Receptors, not specific information on certain glutamate receptors. There was already an NMDA receptor wikipedia article. if we include it here, then there would be no use for the NMDA receptor article. —Preceding unsigned comment added by Justindchien (talk • contribs) 01:22, 26 November 2009 (UTC)